Praxis Precision Medicines Stock Forecast

Sell candidate since Jul 27, 2026 Loss -6.33%

The Praxis Precision Medicines, Inc. stock price fell by -6.33% on the last day (Tuesday, 28th Jul 2026) from $315.80 to $295.81. During the last trading day the stock fluctuated 9.26% from a day low at $290.09 to a day high of $316.96. The price has fallen in 6 of the last 10 days and is down by -9.73% for this period. Volume has increased on the last day by 133 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 424 thousand shares were bought and sold for approximately $125.49 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -5.41% during the next 3 months and, with a 90% probability hold a price between $217.88 and $325.50 at the end of this 3-month period.

PRAX Signals & Forecast

There are few to no technical positive signals at the moment. The Praxis Precision Medicines, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $313.39 and $303.86. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, June 29, 2026, and so far it has fallen -15.62%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Praxis Precision Medicines, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $278.93 and $264.75. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Praxis Precision Medicines, Inc. finds support just below today's level at $278.93. If this is broken, then the next support from accumulated volume will be at $264.75 and $258.08.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $26.87 between high and low, or 9.26%. For the last week, the stock has had daily average volatility of 5.35%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (PRAX) For The Upcoming Trading Day Of Wednesday 29th

For the upcoming trading day on Wednesday, 29th we expect Praxis Precision Medicines, Inc. to open at $300.95, and during the day (based on 14 day Average True Range), to move between $286.55 and $305.07, which gives a possible trading interval of +/-$18.51 (+/-6.46%) up or down from last closing price. If Praxis Precision Medicines, Inc. takes out the full calculated possible swing range there will be an estimated 6.46% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $278.93 (5.71%) than the resistance at $327.79 (10.81%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Praxis Precision Medicines, Inc. stock A Buy?

Praxis Precision Medicines, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.247 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on July 29, 2026 - $300.95 ( 1.74%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk